Daxor Corporation Announces Transition To Securities Exchange Act of 1934 Reporting Company, Reaffirming Focus on Core Blood Volume Analysis and Diagnostic Business
Daxor Corporation - Closed End Fund (DXR)
NASDAQ:AMEX Investor Relations:
daxor.com/investors
Company Research
Source: GlobeNewswire
Oak Ridge, TN, Feb. 10, 2026 (GLOBE NEWSWIRE) -- Daxor Corporation (NASDAQ: DXR), the global leader in blood volume measurement technology, today announced its intention to transition its primary regulatory reporting framework from the Investment Company Act of 1940 (the Investment Company Act) to the Securities Exchange Act of 1934 (the “Exchange Act”), subject to its completion of required regulatory filings and approvals. This transition reflects the sustained rapid scaling and strategic maturation of the Company’s core diagnostic technology operating business. The Company’s principal focus remains the development and commercialization of its market-leading Blood Volume Analysis (BVA) technology. This is the only FDA-cleared diagnostic blood test providing objective, patient-specific quantification of a patient’s total blood volume status and composition. Key Highlights of the Transition Reaffirmed Focus on Operations: This transition validates the success of management’s stra
Show less
Read more
Impact Snapshot
Event Time:
DXR
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
DXR alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
DXR alerts
High impacting Daxor Corporation - Closed End Fund news events
Weekly update
A roundup of the hottest topics
DXR
News
- Daxor Corporation to Showcase Next-Generation Portable Blood Volume Analyzer at ACC.26; Highlighting Clinical Outcomes and Reduced Readmissions [Yahoo! Finance]Yahoo! Finance
- Daxor Corporation to Showcase Next-Generation Portable Blood Volume Analyzer at ACC.26; Highlighting Clinical Outcomes and Reduced ReadmissionsGlobeNewswire
- Daxor Details Portable FDA-Cleared Blood Volume Analyzer, 'Razor-and-Blades' Kit Growth at iAccess Alpha [Yahoo! Finance]Yahoo! Finance
- Daxor Corporation (DXR) Presents at IAccess Alpha Virtual Best Ideas Spring Investment Conference 2026 Prepared Remarks Transcript [Seeking Alpha]Seeking Alpha
- Daxor to Debut New Rapid, Portable Blood Volume Analyzer at SCCM 2026 Critical Care Congress [Yahoo! Finance]Yahoo! Finance
DXR
Sec Filings
- 3/16/26 - Form N-CEN
- 3/2/26 - Form N-CSR
- 3/2/26 - Form NPORT-P
- DXR's page on the SEC website